ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)
$1.93 -0.07 (-3.5%)
Analysed ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) News Sources
Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and ...
14-05-2026
yahoo.com
Big Pharma’s 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
14-05-2026
247wallst.com
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
14-05-2026
yahoo.com
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
26-05-2026
yahoo.com
Allogene Therapeutics Announces Planned CEO Succession
28-05-2026
yahoo.com
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio
07-06-2026
yahoo.com
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
12-06-2026
yahoo.com
How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease
17-06-2026
yahoo.com
Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions
28-06-2026
yahoo.com
Kyverna Therapeutics Sinks 13%: Here’s Why
10-07-2026
247wallst.com
What is the current price of ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)?
The current price of ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) is $1.93.
ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) since the previous trading day is $-0.07.
ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) since the previous trading day is -3.5%.
What is the most recent average sentiment score for ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)?
The most recent average sentiment score for ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) is 69 out of 100.
What is the most recent average sentiment for ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)?
The most recent sentiment for ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ) is .
SEC-8K** Filing Available For ALLOGENE THERAPEUTICS INC (ALLO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.